A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)
A Randomized, Controlled, Open-label, Multicenter Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)
Sponsor: TJ Biopharma Co., Ltd.
Terminated
Company Development strategy adjustment\]
Other terminated trials from TJ Biopharma Co., Ltd.
- Advanced Solid Tumor · Phase PHASE1/PHASE2 · Feb 2023
- Systemic Lupus Erythematosus (SLE) · Phase PHASE1 · Dec 2022
More terminations from TJ Biopharma Co., Ltd.
This PHASE3 trial investigates Myelodysplastic Syndromes(MDS) and is currently terminated or withdrawn. TJ Biopharma Co., Ltd. leads this study, which shows 8 recorded versions since 2023 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
May 2025 — Sep 2025 [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
-
Sep 2024 — May 2025 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE3
▶ Show 3 earlier versions
-
May 2023 — May 2024 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Apr 2023 — May 2023 [monthly]
Not Yet Recruiting PHASE3
-
Mar 2023 — Apr 2023 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- TJ Biopharma Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Bengbu, China , Changchun, China , Changsha, China , Chengdu, China , Chongqing, China , Guangzhou, China , Hangzhou, China , Harbin, China , Hefei, China and 18 more locations